Healthcare / Drug Manufacturers - Specialty & GenericBSE
$975.55
-15.90 (-1.60%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-435.0M · quality 45.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
44/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$154.5B
P/E
38.9x
↑EV/EBITDA
14.1x
↑ROE
5.6%
↑Gross Margin
67.9%
↑Debt/Equity
0.51
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+9.8%
FCF CAGR
—
FCF margin
-2.7%
FCF / Net income
-0.56x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $82.25B · net income $3.98B · FCF $-2.22B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $82.25B | $82.25B | $71.92B | $66.45B | $62.19B |
| Net Income | $3.98B | $3.98B | $8.39B | $771.0M | $-610.0M |
| EBITDA | $12.66B | $12.66B | $15.89B | $8.09B | $7.50B |
| EPS | — | — | 52.85 | 4.86 | -3.83 |
| Gross Margin | 67.9% | 67.9% | 67.8% | 63.5% | 64.3% |
| Operating Margin | 10.0% | 10.0% | 11.2% | 7.9% | 3.7% |
| Net Margin | 4.8% | 4.8% | 11.7% | 1.2% | -1.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.51 | 0.51 | 0.44 | 0.67 | 0.68 |
| Current Ratio | 1.62 | 1.62 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.22B | $-2.22B | $-435.0M | $736.0M | $-1.54B |
| Returns | |||||
| ROE | 5.6% | 5.6% | 13.4% | 1.4% | -1.1% |
| Valuation | |||||
| P/E | 38.90 | 38.90 | 17.57 | 132.57 | — |
| EV/EBITDA | 14.06 | 14.06 | 10.32 | 16.01 | 9.71 |
| P/B | 2.18 | 2.18 | 2.36 | 1.88 | 0.86 |
| Growth & Yield | |||||
| Revenue Growth | 14.4% | 14.4% | 8.2% | 6.8% | — |
| EPS Growth | — | — | 987.4% | 226.9% | — |
| Dividend Yield | 0.5% | 0.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-12.4%
Start / end P/E
n/dx → n/dx
EPS bridge
52.85 → n/d
Residual
-12.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.